PHVS logo

PHARVARIS NV

PHVSNASDAQ
🏆 #1910 by market capEarnings Nov 10 · PostUS Equity
$31.72▼ $0.16 (−0.50%)
After hours · at close
🔔
Track PHVS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.22B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair
No chart data available for PHVS.

Trading Snapshot

Day Range
$31.44 – $32.01
52-Week Range
$20.65 – $43.25
Volume
$2.95B
Avg Volume
$2.23B
Shares Outstanding
69.9M
Next Earnings
Dec 12, 2026

Fundamentals Snapshot

Annual Revenue
$821M
Last Q Revenue
$229M
P/E Ratio
-10.4
P/S Ratio
0.0x
EPS (TTM)
$-2.52
Dividend Yield
0.00%
Dilution (1yr)
+9.4%

Why Investors Own PHVS

  • ✓High-growth profile — revenue up +0.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 69% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PHVS logo

PHARVARIS NV

PHVS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$170M▲ +16.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$137M▲ +13.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.2M▲ +9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$291M▲ +$11M YoY
StockOtter · stockotter.space

About PHARVARIS NV

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$42.44
▲ +33.8% Upside
High Target$53.00
Low Target$36.85
Based on 21 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PHARVARIS NV tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift PHVS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

PHARVARIS NV announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.